

August 07, 2025

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd

Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Further to our intimation dated July 30, 2025 we wish to inform you that the Board of Directors, at its meeting held today, has, inter-alia, approved the following:

1. Recommended a Final Dividend of Rs.3 (150%) per equity share of Rs.2 each for the financial year ended March 31, 2025. The said dividend, if approved at the forthcoming Annual General Meeting ('AGM'), shall be paid on or before October 21, 2025.
2. Approved the Record Date for determining the eligibility of the Shareholders for the purpose of Final Dividend. The same shall be communicated to the Stock Exchanges separately as per the timelines specified under the Listing Regulations.
3. Approved the unaudited standalone and consolidated financial results (**Annexure-1**) and the Limited Review Report of the Company as per Indian Accounting Standards for the quarter ending June 30, 2025. We also enclose a Press Release on the results (**Annexure 2**) and an investor presentation (**Annexure 3**).
4. Approved the convening of the 34th Annual General Meeting of the Company on 22nd September, 2025 through Video Conferencing / Other Audio-Visual means.

The meeting commenced at 11.10 A.M and concluded at 12.45 P.M.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary

Membership No. A23989

Encl: A/a

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

**The Board of Directors of
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Caplin Point Laboratories Limited ('the Company') for the quarter ended June 30, 2025 ('the Statement').
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

The above reports have been furnished to us by the Management, which have been relied upon by us for the purpose of review of this Statement. Our review conclusion is not modified in respect of this matter.

For Brahmayya & Co.,
Chartered Accountants
Firm Regn No. 000511S



N. Sri Krishna
Partner

Membership No. 026575



UDIN: 25026575BMLHKX9939

Place : Chennai

Date : August 7, 2025

| CAPLIN POINT LABORATORIES LIMITED | | | | | |
|---|--|-------------------|-------------------|-------------------|---------------|
| STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 | | | | | |
| | | Quarter Ended | | | Year Ended |
| | Particulars | 30.06.2025 | 31.03.2025 | 30.06.2024 | 31.03.2025 |
| | | (1) | (2) | (3) | (4) |
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| ₹ In Crores | | | | | |
| | Income: | | | | |
| I | Revenue from operations | 182.57 | 173.61 | 185.64 | 752.41 |
| II | Other income | 32.03 | 41.25 | 21.50 | 134.59 |
| III | Total Income (I+II) | 214.60 | 214.86 | 207.14 | 887.00 |
| | | | | | |
| IV | Expenses: | | | | |
| | a. Cost of materials consumed | 38.62 | 34.25 | 36.38 | 136.64 |
| | b. Purchase of traded goods | 13.18 | 17.39 | 16.18 | 77.17 |
| | c. Changes in inventories of finished goods, stock in trade and work in progress | 6.27 | 3.66 | 7.81 | 24.36 |
| | d. Employee benefits expense | 9.63 | 14.39 | 10.86 | 52.13 |
| | e. Finance costs | 0.04 | 0.04 | 0.02 | 0.12 |
| | f. Depreciation & Amortisation Expense | 6.14 | 6.09 | 6.18 | 24.77 |
| | g. Other Expenses | 28.26 | 28.88 | 33.03 | 130.14 |
| | Total Expenses | 102.14 | 104.70 | 110.46 | 445.33 |
| | | | | | |
| V | Profit before exceptional items and Tax (III-IV) | 112.46 | 110.16 | 96.68 | 441.67 |
| VI | Exceptional items | - | - | - | - |
| VII | Profit Before Tax (V-VI) | 112.46 | 110.16 | 96.68 | 441.67 |
| VIII | Tax Expenses | | | | |
| | (1) Current Tax | 26.91 | 23.63 | 24.57 | 102.90 |
| | (2) Deferred Tax | (0.34) | 0.03 | (0.43) | (0.72) |
| | Total Tax Expenses | 26.57 | 23.66 | 24.14 | 102.18 |
| IX | Net Profit for the period (VII-VIII) | 85.89 | 86.50 | 72.54 | 339.49 |
| X | Other Comprehensive Income/ (Loss) - Net of Tax | | | | |
| | A. Items that will not be re-classified to profit or loss | | | | |
| | i) Remeasurements of Defined Benefit Plan | - | (0.29) | - | (0.13) |
| | ii) Income tax relating to these items | - | 0.07 | - | 0.03 |
| XI | Total Comprehensive Income For The Period (IX+X) | 85.89 | 86.28 | 72.54 | 339.39 |
| XII | Paid up Equity Share Capital (Face value of shares of Rs 2/- each) | 15.20 | 15.20 | 15.20 | 15.20 |
| XIII | Other equity | - | - | - | 1,685.73 |
| XIV | Earnings Per Share (EPS) of Face value Rs 2/- per Equity share* | | | | |
| | (a) Basic (in Rupees) | 11.30 | 11.37 | 9.55 | 44.67 |
| | (b) Diluted (in Rupees) | 11.26 | 11.35 | 9.50 | 44.47 |
| | | *(Not Annualised) | *(Not Annualised) | *(Not Annualised) | *(Annualised) |

See Accompanying notes to Financial Results



CAPLIN POINT LABORATORIES LIMITED


Standalone Notes:

- 1) The above Unaudited Standalone financial Results for the Quarter ended June 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 7, 2025. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued unmodified report thereon.
- 2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore has only one reportable segment in accordance with Ind AS 108 "Operating Segments". Hence no separate segment reporting is applicable to the Company.

- 4) Other Income and Profit Before Tax includes:

| Particulars | ₹ In Crores | | | |
|--|---------------|------------|------------|------------|
| | Quarter Ended | | | Year Ended |
| | 30.06.2025 | 31.03.2025 | 30.06.2024 | 31.03.2025 |
| Dividend from wholly owned subsidiary Caplin Point Far East Limited | 8.12 | 15.14 | - | 35.53 |


- 5) During the quarter ended June 30, 2025 and March 31, 2025 the Company had allotted NIL equity shares of ₹ 2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as at June 30, 2025. The Company had allotted 68,550 equity shares during the quarter ended June 30, 2024.
- 6) The Board of Directors at their meeting held on 15th May, 2025 declared an interim dividend of ₹3.00 (Rs. Three Only) per equity share (150 %) for the financial year 2024-25 and was paid to the shareholders on 9th June 2025. The Board of Directors at their meeting held today have recommended a final dividend of ₹.....3...../- per equity share (150%) for the financial year 2024-25 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company. The total dividend for the financial year 2024-25 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be ₹.....6...../- per equity share (300.0%) of the face value of ₹ 2 each.
- 7) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.



Place: Chennai
Date: August 7, 2025

For and on behalf of the Board

Dr. Sridhar Ganesan
Managing Director



Independent Auditor's Review Report on Unaudited Consolidated Quarterly and Year to Date Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

**The Board of Directors of
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Caplin Point Laboratories Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its share of net profit / (loss) after tax and total comprehensive income / loss of associate for the quarter ended June 30, 2025 being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and in compliance with Regulation 33 of Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.



4. The statement includes results of the following entities:

Subsidiary Companies

| Name of the Entity | Relationship |
|---|-------------------------|
| Caplin Steriles Limited, India | Subsidiary |
| Argus Salud Pharma LLP, India | Subsidiary |
| Caplin One Labs Limited, India (Formerly known as Caplin Onco Limited) | Wholly owned subsidiary |
| Caplin Point Far East Limited, Hong Kong | Wholly owned subsidiary |
| Caplin Point (S) Pte. Ltd, Singapore | Wholly owned subsidiary |

Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)

| Name of the Entity | Relationship |
|---|----------------------|
| Caplin Point EL Salvador, S.A. DE C.V., El Salvador | Step Down Subsidiary |
| Nuevos Eticos Neo Ethicals S.A, Guatemala | Step Down Subsidiary |
| Neoethicals CIA.LTDA, Ecuador | Step Down Subsidiary |
| Drogueria Saimed de Honduras S.A., Honduras | Step Down Subsidiary |
| Neo Ethicals S.A, Nicaragua | Step Down Subsidiary |
| Caplin Point Laboratories Colombia SAS, Colombia | Step Down Subsidiary |
| Neoethicals Chile SpA | Step Down Subsidiary |
| Triwin Pharma S.A DE C.V | Step Down Subsidiary |

Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)

| Name of the Entity | Relationship |
|-------------------------------|----------------------|
| Caplin Steriles USA Inc., USA | Step Down Subsidiary |



Associate Company of Caplin Steriles Limited

| Name of the Entity | Relationship |
|-------------------------------|--------------|
| Sunsole Solar Private Limited | Associate |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statement / financial information / financial results of four subsidiaries and six step-down subsidiaries included in the Statement, whose interim financial statement / financial information / financial results reflect total revenues of Rs. 458.39 Crores, total net profit after tax of Rs. 65.28 Crores and total comprehensive income of Rs. 65.74 Crores for the quarter ended on June 30, 2025, as considered in the Unaudited Consolidated Financial Results have not been reviewed by us. These interim financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in Paragraph 3 above. Our conclusion on the statement is not modified in respect of this matter.
7. The Statement includes the interim financial statement / financial information / financial results of one subsidiary, three step-down subsidiary and one associate, which have not been reviewed, whose interim financial statement / financial information / financial results reflect total revenues of 17.69 Crores, net profit after tax of Rs. 1.75 Crores and total comprehensive income of Rs. 1.65 Crores for the quarter ended June 30, 2025, as considered in the Unaudited Consolidated Financial Result. The Statement also includes the Group's share of net profit of Rs. 0.03 Crores and total comprehensive income of Rs. 0.00 Crores for the quarter ended June 30, 2025 as considered in the unaudited consolidated financial result, in respect of one associate, based on their interim financial statements / financial information / financial results, which have not been reviewed. According to the information and explanations given to us by the management, these financial statements / financial information / financial results of aforesaid subsidiaries and associate are not material to the Group. Our conclusion on the statement is not modified in respect of the above matter.



The above reports have been furnished to us by management, which have been relied upon by us for the purpose of review of this Statement. Our review conclusion is not modified in respect of this matter.

For Brahmayya & Co.,
Chartered Accountants
Firm Regn No: 000511S





A handwritten signature in black ink, appearing to be "N. Sri Krishna".

N. Sri Krishna
Partner
Membership No.026575
UDIN: 25026575BMLHKY2529

Place : Chennai
Date : August 07, 2025

| CAPLIN POINT LABORATORIES LIMITED | | | | | |
|---|-------------------|-------------------|-------------------|-----------------|--|
| STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 | | | | | |
| Particulars | Quarter Ended | | | Year Ended | |
| | 30.06.2025 | 31.03.2025 | 30.06.2024 | 31.03.2025 | |
| | (1) | (2) | (3) | (4) | |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) | |
| ₹ in Crores | | | | | |
| Income: | | | | | |
| I Revenue from operations | 510.22 | 502.45 | 458.96 | 1,937.47 | |
| II Other income | 23.14 | 25.74 | 18.56 | 96.43 | |
| III Total Income (I+II) | 533.36 | 528.19 | 477.52 | 2,033.90 | |
| IV Expenses: | | | | | |
| a. Cost of materials consumed | 73.51 | 60.84 | 58.58 | 248.45 | |
| b. Purchase of traded goods | 113.50 | 138.77 | 120.45 | 575.70 | |
| c. Changes in inventories of finished goods, stock in trade and work in progress | 8.23 | 1.59 | 6.45 | (53.31) | |
| d. Employee benefits expense | 43.16 | 46.51 | 40.15 | 177.72 | |
| e. Finance costs | 0.18 | 0.17 | 0.05 | 0.61 | |
| f. Depreciation & Amortisation Expense | 16.29 | 17.04 | 15.96 | 65.96 | |
| g. Other Expenses | 94.06 | 86.68 | 81.52 | 341.98 | |
| Total Expenses | 348.93 | 351.60 | 323.16 | 1,357.11 | |
| V Profit before share of profit in Associate, Exceptional Items and tax (III-IV) | 184.43 | 176.59 | 154.36 | 676.79 | |
| VI Share of Profit/(Loss) in Associate | 0.03 | 0.08 | 0.02 | (0.01) | |
| VII Exceptional items | - | - | - | - | |
| VIII Profit Before Tax (V+VI+VII) | 184.46 | 176.67 | 154.38 | 676.78 | |
| IX Tax Expenses | | | | | |
| (1) Current Tax | 33.10 | 29.27 | 29.38 | 125.33 | |
| (2) Deferred Tax | 0.60 | 2.12 | 0.08 | 10.36 | |
| Total Tax Expenses | 33.70 | 31.39 | 29.46 | 135.69 | |
| X Net Profit for the period (VIII - IX) | 150.76 | 145.28 | 124.92 | 541.09 | |
| XI Other Comprehensive Income - Net of Tax | | | | | |
| A. Items that will not be re-classified to profit or loss | | | | | |
| i) Remeasurements of Defined Benefit Plan | - | (0.28) | - | 0.14 | |
| ii) Income tax relating to these items | - | 0.07 | - | (0.04) | |
| B. Items that will be re-classified to profit or loss | | | | | |
| i) Exchange difference in translating the financial statements of foreign operations | 0.36 | (1.54) | 4.68 | 26.97 | |
| XII Total Comprehensive Income For The Period (X + XI) | 151.12 | 143.53 | 129.60 | 568.16 | |
| XIII Profit attributable to: | | | | | |
| Owners of the Company | 152.80 | 142.57 | 123.97 | 536.31 | |
| Non- controlling interests | (2.04) | 2.71 | 0.95 | 4.78 | |
| | 150.76 | 145.28 | 124.92 | 541.09 | |
| XIV Total Comprehensive Income For The Period attributable to | | | | | |
| Owners of the Company | 153.16 | 140.82 | 128.65 | 563.38 | |
| Non- controlling interests | (2.04) | 2.71 | 0.95 | 4.78 | |
| | 151.12 | 143.53 | 129.60 | 568.16 | |
| XV Paid up Equity Share Capital (Face value of share of Rs 2/- each) | 15.20 | 15.20 | 15.20 | 15.20 | |
| XVI Other equity excluding Non-controlling interest | | | | 2,835.29 | |
| XVII Earnings Per Share (EPS) of Face value Rs 2/- per Equity share* | | | | | |
| (a) Basic (in Rupees) | 20.10 | 18.75 | 16.32 | 70.57 | |
| (b) Diluted (in Rupees) | 20.03 | 18.69 | 16.24 | 70.25 | |
| | *(Not Annualised) | *(Not Annualised) | *(Not Annualised) | *(Annualised) | |

See Accompanying notes to Financial Results



CAPLIN POINT LABORATORIES LIMITED
Segment Information- Revenues and Results

| Particulars | Quarter Ended | | | Year Ended |
|---|---------------|---------------|---------------|-----------------|
| | 30.06.2025 | 31.03.2025 | 30.06.2024 | 31.03.2025 |
| | (1) | (2) | (3) | (4) |
| | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| ₹ In Crores | | | | |
| 1) Segment revenue (Total Revenue) | | | | |
| Rest of the World | 403.53 | 406.12 | 381.06 | 1,582.96 |
| USA | 106.69 | 96.33 | 77.90 | 354.51 |
| Unallocated | 23.14 | 25.74 | 18.56 | 96.43 |
| Total | 533.36 | 528.19 | 477.52 | 2,033.90 |
| 2) Segment results (PBT) | | | | |
| Rest of the World | 151.46 | 135.47 | 131.59 | 540.34 |
| USA | 9.86 | 15.46 | 4.22 | 40.01 |
| Unallocated | 23.14 | 25.74 | 18.57 | 96.43 |
| Total | 184.46 | 176.67 | 154.38 | 676.78 |



CAPLIN POINT LABORATORIES LIMITED

Consolidated Notes:


- 1) The above Unaudited Consolidated financial Results for the Quarter ended June 30, 2025 were recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 7, 2025. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued unmodified report thereon.
- 2) The Unaudited Consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3) The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – *Operating Segments*. **Segment 1:** Rest of the World. **Segment 2:** United States of America (USA) Accordingly, segment reporting has been presented along with the Consolidated results.
- 4) As regards the pending Insurance claim, the matter is currently pending before legal forum which will be dealt with appropriately upon reaching the finality. Accordingly, CSL will continue to recognize the insurance claim as recoverable.
- 5) During the quarter ended June 30, 2025 and March 31, 2025 the Company had allotted NIL equity shares of ₹ 2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as at June 30, 2025. The Company had allotted 68,550 equity shares during the quarter ended June 30, 2024.
- 6) During the quarter ended June 30, 2025 the Company's wholly owned Subsidiary Caplin Point Far East Limited, Hong Kong has acquired 100% shares of Neo Ethicals Chile SpA with effect from 1st April, 2025 and Triwin Pharma S.A DE C.V (Mexico) with effect from 3rd June, 2025. The results of both these Step down subsidiaries have been Consolidated in the current quarter results.
- 7) The Board of Directors at their meeting held on 15th May, 2025 declared an interim dividend of ₹3.00 (Rs. Three Only) per equity share (150 %) for the financial year 2024-25 and was paid to the shareholders on 9th June 2025. The Board of Directors at their meeting held today have recommended a final dividend of ₹...3.../- per equity share (150%) for the financial year 2024-25 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company.

The total dividend for the financial year 2024-25 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be ₹...6.../- per equity share (300%) of the face value of ₹ 2 each.
- 8) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.

Place: Chennai
Date: August 7, 2025



For and on behalf of the Board


Dr. Sridhar Ganesan
Managing Director

Q1 FY26 Total Revenue at ₹533 Crores; an increase of 11.7% YoY

Q1 FY26 PAT at ₹151 Crores; an increase of 20.7% YoY

US Market Q1 FY26 Total Revenue ₹108.5 Crores; an increase of 36% YoY

Q1 FY26 EBITDA crosses ₹200 Crores; an increase of 17.9% YoY

Free Cash Reserves at ₹1,237 Crores; Liquid Assets at ₹2,207 Crores

Chennai, 7th August 2025: Caplin Point Laboratories Ltd. (“Caplin Point” or the “Company”) (BSE: 524742 | NSE: CAPLIPOINT), a rapidly expanding and fully integrated pharmaceutical company with a leading market position in Latin America, today announced its financial performance for the quarter ended June 30, 2025.

Consolidated Financial Performance for Q1 FY26:

₹ in Crores

| Particulars | Q1 FY 26 | Q1 FY 25 | YoY (%) | Q4 FY 25 | QoQ (%) | 12M FY25 | 12M FY24 | YoY (%) |
|------------------------|----------|----------|---------|----------|---------|----------|----------|---------|
| Revenue from Operation | 510.2 | 459.0 | 11.2% | 502.5 | 1.5% | 1,937.5 | 1,694.1 | 14.4% |
| Total Revenue | 533.4 | 477.5 | 11.7% | 528.2 | 1.0% | 2,033.9 | 1,761.0 | 15.5% |
| Gross Profit | 315.0 | 273.5 | 15.2% | 301.3 | 4.6% | 1,166.6 | 969.9 | 20.3% |
| Gross Margin % | 61.7% | 59.6% | | 60.0% | | 60.2% | 57.3% | |
| EBITDA | 200.9 | 170.4 | 17.9% | 193.8 | 3.7% | 743.4 | 618.4 | 20.2% |
| EBITDA Margin % | 37.7% | 35.7% | | 36.7% | | 36.5% | 35.1% | |
| Profit Before Tax | 184.5 | 154.4 | 19.5% | 176.7 | 4.4% | 676.8 | 564.4 | 19.9% |
| PBT Margin % | 34.6% | 32.3% | | 33.4% | | 33.3% | 32.1% | |
| Profit after Tax | 150.8 | 124.9 | 20.7% | 145.3 | 3.8% | 541.1 | 461.4 | 17.3% |
| PAT Margin | 28.3% | 26.2% | | 27.5% | | 26.6% | 26.2% | |

Other Consolidated Financial Highlights for Q1 FY26:

- Gross Margin for Q1 FY26 is 61.7% vs 59.6% in Q1 FY25 aided by new product launches across existing and new markets.
- EBITDA Margin for Q1 FY26 is at 37.7% vs 35.7% in Q1 FY25.
- Basic EPS increased by 23.1% to ₹20.10 in Q1 FY26 compared to ₹16.32 in Q1 FY25.
- Cash Flow from Operations in Q1 FY26 is ₹118 Crores vs ₹96 Crores in Q1 FY25.
- Free Cash Flow is ₹53 Crores (after Capex investment of ₹65 Crores) in Q1 FY26 as compared to ₹59 Crores (after capex investment of ₹37 Crores) in Q1 FY25.
- Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for Q1 FY26 is in the range of 79% and 21% respectively.
- CSL's Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for Q1 FY26 in the range of 85% and 15% respectively.
- As of 30th June 2025, Inventories are at ₹324 Crores - 56% Stock at the warehouses, close to the customer; In Transit 13%; 31% in India. Receivables are at 114 days.
- As of 30th June 2025, Free Cash reserves are at ₹1,237 Crores and Total Liquid Assets at ₹2,207 Crores.

Business Highlights for Q1 FY26:**Emerging Markets:**

- Company deepens its strong presence in Latin America with a new warehouse in Chile, one of the key targets for growth in larger LatAm markets. Chile is a mix of Tender and Private markets and Caplin is well positioned to participate in both with over 120+ product registrations and multiple more in pipeline.
- Company lays out pathway for “China 2.0”, a move to align strategically with multiple partners in China (both new and existing ones), for partnerships on Peptides, Biosimilars and other Complex products, to be filed and commercialized in LatAm and Regulated markets, through asset-light model again.
- Mexico Update – Company has filed 35+ products, with 17 approvals received. Working on a pipeline of 80+ products, to be filed within the next 12 months, through Internal and China 2.0 partners.
- Company has won tenders to the tune of US\$7.6 million in one of the key CentAm markets, to be supplied within Q2 and Q3-FY26.
- As part of alignment with global push towards “Onshored Manufacturing”, Company is procuring land/buildings in Mexico and Guatemala and plans to manufacture Oral Liquids and Dermatology range of products, in the first phase.
- API unit for General Category products at Vizag is completed, with GMP certification work under progress. Plans to start backward integration process on certain key injectable/OSD products for LatAm first and US/EU DMF filings in second phase.
- Construction ongoing at full swing at Oncology API site in Thervoy, near Chennai. Facility expected to be completed within 12 months and will cater to Company’s budding Oncology business for Regulated and Emerging Markets.
- Company in talks with players in EU and China to work synergistically on Biosimilar products, with a new fill-finish facility in India under plans. More information on this area within the next 2 Quarters.

US & Regulated Markets:

- Caplin Steriles Limited (CSL) continues robust growth in both B2B and B2C segments, with strong finish to Q1. Order book remains healthy for Q2~Q4 as well.
- Company currently has 38 ANDAs approved with a further 13 ANDAs under review, setting the stage for strong growth in top and bottom line for the next few quarters.
- CSL is in active discussions to acquire ANDAs from outside, in addition to the 3 acquired in the last few months, to augment growing presence in US and other Regulated markets.
- Company sees good momentum from new specialty product launches such as Injectable Bags, Ophthalmic Emulsion, Injectable Emulsion and Plastic Vial products in US and Canada.
- Company is on target to file 7 Pre-Filled Syringe products (Line-6) within the next 12 months, which is an area with limited competition. Plans will also file GLP-1 products (Cartridges) from this line, in Emerging Markets.
- Company has filed more products and expecting approvals in multiple non-US markets: Canada (16 filed and 10 approved), Mexico (11 approved), Saudi Arabia (7 filed), UAE (8 filed and 4 approved) and South Africa (10 filed) amongst others. Meaningful revenue expected from these markets including Brazil in the coming years.

- Company is actively seeking out acquisition of land/plants in the US. Initial plans are to warehouse our own products before moving to Packaging and eventually Manufacturing, if commercial viability is established.
- **Update on Caplin Steriles USA Inc (CSU) - company's own label in the US:**
 - Company's front end achieves revenue of \$3.2 million from inception till date (around 8 months), with excellent profitability. CSU reaches profitability with adequate cashflows within the first year of operations.
 - CSU has launched 24 products till date, with a further 15+ products to be launched in FY26.
 - Company is in active discussions to in-license 5 injectable products from globally renowned CMO's.
 - Company has entered into contracts with all large and mid-sized Wholesalers in the US, with weekly ordering cycles established with the Big 4.
 - Company enters into supply agreements with 30+ direct buyers (IDNs and Hospital Systems) in the US, with ongoing discussions with 25+ more health systems. CSU targets maximum revenue through these direct buyers in the next 24 months.
 - Total number of end users (Hospitals, Pharmacies, Clinics etc) currently buying CSU label products – 5610.
 - Company targets highly profitable CSU revenues to offset potential dip in milestone revenues from B2B partners going forward.

Commenting on the performance, Mr. C.C. Paarthipan, Chairman said:


We're putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows.

Strategic Growth Initiatives

| Project Summary | | | | | |
|--------------------------|--------------------------------|--|--|--|----------------------|
| Facility | Location | Product | Target Market | Status | Timeline |
| Caplin Plant I | CP1, Suthukeny, Puducherry | Lyophilized Injectables and Dual Chamber Syringes. | Existing Markets | Nearing Completion | Q3 FY26 |
| Caplin Steriles Phase II | CP4, Gummidipoondi, Chennai | Injectable Vials and Pre-Filled Syringes | Regulated Markets | Line 5 – Completed. Line 6 – Completed. | Completed |
| API Facility upgradation | Visakhapatnam, Andhra Pradesh | General API | Existing and Regulated Markets | Completed | Completed |
| Oncology Facility | SIDCO, Kakkalur (Near Chennai) | OSD & Injectable phase | Existing and Regulated Markets | OSD – Completed Injectable – Nearing Completion | Injectable – Q2 FY26 |
| Oncology API Facility | Thervoy SIPCOT, Chennai | Oncology API | Existing and Regulated Markets | Civil activity ongoing at full swing. | Q4 FY26 |
| OSD Facility | Puducherry | Oral Solid Dosages | Existing Market along with Mexico, Brazil, US and EU | Design drawing process in progress | Q3 FY27 |
| COL* Injectable Facility | Gummidipoondi, Chennai | Injectables and Ophthalmics | Existing and Regulated Markets | Civil & Structural activity ongoing | Q4 FY27 |

*Caplin One Labs Limited

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.



Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company also has a growing presence in the regulated markets such as US through its Subsidiary Caplin Steriles Limited and Caplin Steriles USA Inc.

Caplin Point listed on Forbes “Asia’s 200 Best Under a Billion” list for 2024. Company has appeared for the **SEVENTH** time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.

For further information, please contact:

G Venkatram,
General Counsel & Company Secretary
Caplin Point Laboratories

+91 44 2496 8000

investor@caplinpoint.net

Simran Malhotra / Akshay Hirani
Churchgate Partners

+91 22 6169 5988

caplinpoint@churchgatepartners.com

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor its directors, or any of its subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.



EARNINGS PRESENTATION Q1 FY26

Rated #1 in India for “*Most Consistent Profitable Growth across the last 10 years*”


*Second Largest wealth creator for the decade ending 2020**

August 2025 | www.caplinpoint.net

#Value Research magazine – Wealth Insight June 2022 issue

*The Economic Times






Evolution Over the Decades








Contract manufacturer

-  Market-led Company
-  Plain vanilla generic products
-  Introducing products that plugged marketplace gaps
-  Negative-working capital business
-  2 main geographies 10 countries (Latin America & Francophone Africa)

Becoming a responsible pharma company


-  Technology and research-led marketing Company
-  Mix of generics, branded generics and specialty molecules and Injectables
-  Launch specialty niche products that Create new markets in varied therapy segments
-  Selective use of Credit strategy to increase market share and remain cash surplus
-  Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly

Diversified Product Portfolio


-  4,000+ Products registered and 650+ Pharmaceutical formulations
-  36 Therapeutic Segments
-  Product mix covers over 65% of WHO essential drug list
-  Latest focus towards complex spaces
-  Accounts for larger shelf share across pharmacies on account of a widening product basket

Q1 FY26 Income Statement


Revenue from Operations




Gross Profit




EBITDA




EBIT



PAT




Earnings Per Share




(All figures in Rs. Crores except EPS in Rs.)

Q1 FY26 Profit Margins


Gross Profit Margins (%)




EBITDA Margins (%)



EBIT Margins (%)




PAT Margins (%)




FY25 Income Statement


Revenue from Operations




Gross Profit




EBITDA




EBIT



PAT



Profit Margins



(All figures in Rs. Crores)

Leadership Team

Chairman Perspectives



Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said:

We're putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows.

Management Team

Dr. Sridhar Ganesan

- Managing Director



Mr. Vivek Partheeban

- Chief Operating Officer



Mr. D Muralidharan

- Chief Financial Officer



Mr. Ashok Partheeban

- Business Head, LATAM



Q1 FY26 Highlights (Emerging Markets)

01

Company strengthens foothold in Latin America with new Warehouse in Chile, a key growth market. With 120+ product registrations and several more in pipeline, Company is well placed across Tender and Private segments.

02

Company initiates "China 2.0" strategy, aligning with new and existing partners for collaborations in Peptides, Biosimilars and Complex products, aimed at LatAm and Regulated markets through asset-light model.

03

Mexico Update – Company has filed 35+ products, with 17 approvals received. Pipeline of 80+ products to be filed over next 12 months through Internal sources and China 2.0 partners.

04

Company has won tenders to the tune of US\$7.6 million in one of the key CentAm markets, to be supplied within Q2 and Q3-FY26.

Emerging Markets Business Highlights

As part of alignment with global push towards "Onshored Manufacturing", Company is procuring land/buildings in Mexico and Guatemala and plans to manufacture Oral Liquids and Dermatology range of products, in the first phase.

05

General API unit at Vizag completed, with GMP certification in progress. Backward integration to commence for select Injectable and OSD products for LatAm, followed by DMF filings for US and EU in subsequent phase.

06

Construction progressing at full pace at Oncology API site in Thervoy, near Chennai. Facility expected to be completed in 12 months, supporting Company's growing Oncology portfolio for Regulated and Emerging Markets.

07

Company in talks with players in EU and China to work synergistically on Biosimilar products, with a new fill-finish facility in India under plans. More information on this area within the next 2 Quarters.

08

Q1 FY26 Highlights (US and Regulated markets)

01

Caplin Steriles reports strong Q1 performance across B2B and B2C segments. Order book remains healthy, providing visibility through Q2 to Q4.

02

Company has 38 ANDAs approved and 13 under review, positioning well for strong top and bottom-line growth over the upcoming quarters.

03

CSL actively exploring additional ANDA acquisitions, building on 3 recent deals, to strengthen presence in the US and other Regulated markets.

04

Strong traction observed from recent specialty launches including Injectable Bags, Ophthalmic Emulsions, Injectable Emulsions, and Plastic Vial products across US and Canada.

US & Regulated Markets Business Highlights

Company is on target to file 7 Pre-Filled Syringe products (Line-6) over the next 12 months, targeting a niche segment with limited competition. Plans also underway to file GLP-1 Cartridge products for Emerging Markets from this line.

05

Growing traction in non-US markets with multiple filings and approvals across Canada, Mexico, Saudi Arabia, UAE and South Africa. Brazil and others expected to contribute meaningfully in the coming years.

06


Company exploring land/plant acquisitions in the US, with phased plans starting from warehousing to packaging and potential manufacturing based on commercial viability.

07

CSU achieves \$3.2M revenue and profitability within 8 months. 24 products launched, 15+ more planned in FY26. In-licensing 5 injectables from global CMOs. Partnered with major wholesalers and 30+ direct buyers. End-user base at 5,610. CSU's high-margin revenue to offset potential B2B milestone declines.





08

Research & Development Capabilities



■ R&D Expense (Rs. Crore)

— R&D Expense as a % of Operating Revenue




*Source – CNBC-TV18, Dec 31st 2020


*Including Partners and Bought Out

Revenue Break up and Manufacturing Strategy


FY25 Operating Revenue



Revenue by Business Segment
(Emerging Markets)




Revenue by Channel
(Emerging Markets)




Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with total revenue of Rs. 2,034 Cr in FY25

Manufacturing & Outsourcing



Exports



- The products produced **inhouse**
- The products are **outsourced** from quality-conscious partners in India and China

Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

Generics and Branded Generics Product Mix



Non-Steroidal Antiinflammatory
Drugs-NSAIDS



Anthelmintics/ Dewormer



Analgesic



Antibiotic and Antifungal



Antihypertensive drug



Electrolytes

Caplin Point Structure

Caplin Point Laboratories (BSE: 524742| NSE: CAPLIPOINT)

Manufacturing Units:

- CP I: Puducherry
- CP X: Vishakhapatnam

Research & Development:

- CP III: Amaris Clinical CRO, Chengalpattu
- CP VI: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Hyderabad
- CP VII: TICEL Bio-Park Bioequivalent dosage forms, Taramani, Chennai
- CP VIII: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Perungudi, Chennai

Subsidiaries of CPL

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

Caplin Point Far East Ltd

Subsidiaries

- Nuevos Eticos Neo Ethicals S.A. Guatemala
- Neo Ethicals S.A. Nicaragua
- Drogueria Saimed de Honduras S.A
- Caplin Point El Salvador, S.A. DE C.V.
- Neoethicals CIA. LTDA Ecuador
- Caplin Point Laboratories Colombia SAS
- Neo Ethicals Chile SpA.
- Triwin Pharma S.A DE C.V Mexico

Caplin One Labs Ltd (COL)

Manufacturing Unit:

- SIDCO, Kakkalur (Near Chennai)
- Gummidipoondi, Chennai

Caplin Steriles Ltd (India)

Manufacturing Units:

- CP IV: Gummidipoondi

Research & Development:


- Perungudi, Chennai
- Gummidipoondi

Caplin Steriles USA Inc (US)

Distribution:

- Front-end trading arm for the sale of products in the USA
- Sunsole Solar Private Ltd (Associate of CSL)

Manufacturing and R&D Platform



Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam



Note. CP III and CP VII are for Research and Development



CP I
Puducherry



CP III
Chengalpattu



CP IV
Gummidipoondi



CP VI
Hyderabad



**Corporate Office and other
R&D units:**
Chennai



CP VII
Chennai

Strategic Investments

| Project Summary | | | | | |
|--------------------------|--------------------------------|--|--|---|----------------------|
| Facility | Location | Product | Target Market | Status | Timeline |
| Caplin Plant I | CP1, Suthukeny, Puducherry | Lyophilized Injectables and Dual Chamber Syringes. | Existing Markets | Nearing Completion | Q3 FY26 |
| Caplin Steriles Phase II | CP4, Gummidipoondi, Chennai | Injectable Vials and Pre-Filled Syringes | Regulated Markets | Line 5 – Completed. Line 6 – Completed. | Completed |
| API Facility upgradation | Visakhapatnam, Andhra Pradesh | General API | Existing and Regulated Markets | Completed | Completed |
| Oncology Facility | SIDCO, Kakkalur (Near Chennai) | OSD & Injectable phase | Existing and Regulated Markets | OSD – Completed Injectable –Nearing Completion | Injectable – Q2 FY26 |
| Oncology API Facility | Thervoy SIPCOT, Chennai | Oncology API | Existing and Regulated Markets | Civil activity ongoing at full swing | Q4 FY26 |
| OSD Facility | Puducherry | Oral Solid Dosages | Existing Market along with Mexico, Brazil, US and EU | Design drawing process in progress | Q3 FY27 |
| COL* Injectable Facility | Gummidipoondi, Chennai | Injectables and Ophthalmics | Existing and Regulated Markets | Civil & Structural activity ongoing | Q4 FY27 |

* Caplin One Labs Limited

Caplin Point has allocated an enhanced Capex budget of approximately Rs.1,000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process

Caplin Point's Investment Case

Core Business to show consistent growth

Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at a steady pace with industry-average margins and benchmark cashflows

US Business to Boost the Growth

Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth

Backed by Enhanced Value Chain

Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

Strong Balance Sheet

Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision

Expansion into Other Geographies and Widening of the Portfolio

Caplin plans to enter more regulated markets such as Canada, Australia, MENA, Russia/CIS as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Strong operational performance driven by key pillars of Caplin's Engines

Experienced and Visionary Board of Directors



Mr. C.C. Paarthipan
Chairman

30+ Years of experience in the pharmaceutical industry

Spearheading the group in its multi-pronged growth approach

First Gen Entrepreneur with a focus towards bottom of the pyramid



Dr. Sridhar Ganesan
Managing Director

35+ Years experience in Pharmaceutical Industry

Previously, held leadership positions in several international assignments

The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

Has been a Faculty in BITS



Dr. C K Gariyali, IAS
Independent Director

Retired IAS Officer and holds a Doctorate in Women Studies

Was Principal Secretary to the Governor of Tamil Nadu from 2005-08

Was Secretary to Hon'ble CM of Tamil Nadu

Worked with various International Agencies like World Bank etc.



Dr. R Nagendran
Independent Director

Ph.D in Ecology and Ethology and M.SC in Zoology

Former Expert Member of the National Green Tribunal and former Head of Department of Environmental Science in St. Joseph's College, Bangalore.



Mr S Deenadayalan
Independent Director

Post Graduate degree in Social Work from Madras School of Social Work and Under Graduate degree in Sociology from Annamalai University

Has extensively worked and mentors individuals enabling them to become successful professionals and more than 30,000 municipal school students have been benefitted by his idealistic model.



Mr. R. Vijayaraghavan
Independent Director

35+ years of experience as a taxation expert with consulting and litigation practice across India

Advises major corporate groups in South India on Direct Taxes, Tax Planning, Tax Litigations

Specializes in advising on taxation of non-residents, joint ventures & collaborations, double taxation avoidance agreements & transfer pricing issues.


Q1 FY26 Consolidated Income Statement

| (Rs. in Cr) | Q1 FY26 | Q1 FY25 | YoY (%) | Q4 FY25 | QoQ (%) | FY25 | FY24 | YoY (%) |
|---|---------------|---------------|--------------|---------------|-------------|-----------------|-----------------|--------------|
| Revenue from Operation | 510.22 | 458.96 | 11.2% | 502.45 | 1.5% | 1,937.47 | 1,694.10 | 14.4% |
| Other Income | 23.14 | 18.56 | 24.7% | 25.74 | (10.1)% | 96.43 | 66.94 | |
| Total Revenue | 533.36 | 477.52 | 11.7% | 528.19 | 1.0% | 2,033.90 | 1,761.04 | 15.5% |
| Cost of Goods sold | 195.24 | 185.48 | 5.3% | 201.20 | (3.0)% | 770.84 | 724.18 | 6.4% |
| Gross Profit (Excluding Other Income) | 314.98 | 273.48 | 15.2% | 301.25 | 4.6% | 1,166.63 | 969.92 | 20.3% |
| <i>Gross Profit Margin (on Rev from Operations)</i> | 61.7% | 59.6% | | 60.0% | | 60.2% | 57.3% | |
| Employee Benefit Expenses | 43.16 | 40.15 | 7.5% | 46.51 | (7.2)% | 177.72 | 143.59 | 23.8% |
| Research and Development expenses | 17.96 | 19.20 | (6.4)% | 19.68 | (8.7)% | 76.68 | 73.72 | 4.0% |
| Other operating expenses | 76.10 | 62.32 | 22.1% | 67.00 | 13.6% | 265.30 | 201.17 | 31.9% |
| Total expenditure | 137.22 | 121.67 | 12.8% | 133.19 | 3.0% | 519.70 | 418.48 | 24.2% |
| EBITDA | 200.90 | 170.37 | 17.9% | 193.80 | 3.7% | 743.36 | 618.38 | 20.2% |
| <i>EBITDA Margin</i> | 37.7% | 35.7% | | 36.7% | | 36.5% | 35.1% | |
| Depreciation and Amortisation | 16.29 | 15.96 | 2.1% | 17.04 | (4.4)% | 65.96 | 53.44 | 23.4% |
| EBIT | 184.61 | 154.41 | 19.6% | 176.76 | 4.4% | 677.40 | 564.94 | 19.9% |
| <i>EBIT Margin</i> | 34.6% | 32.3% | | 33.5% | | 33.3% | 32.1% | |
| Finance Cost | 0.18 | 0.05 | | 0.17 | | 0.61 | 0.78 | |
| Share of Profit/(Loss) in associates | 0.03 | 0.02 | | 0.08 | | (0.01) | 0.27 | |
| Profit Before Tax | 184.46 | 154.38 | 19.5% | 176.67 | 4.4% | 676.78 | 564.43 | 19.9% |
| <i>PBT Margin</i> | 34.6% | 32.3% | | 33.4% | | 33.3% | 32.1% | |
| Tax | 33.70 | 29.46 | | 31.39 | 7.4% | 135.69 | 103.01 | 31.7% |
| Profit after Tax | 150.76 | 124.92 | 20.7% | 145.28 | 3.8% | 541.09 | 461.42 | 17.3% |
| <i>PAT Margin</i> | 28.3% | 26.2% | | 27.5% | | 26.6% | 26.2% | |

Visit Our Real Time ESG Disclosure Platform

At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations.

Click to access ESG Profile



Caplin Point ESG Profile Link ([Click Here](#))

<https://www.caplinpoint.net/>

Disclaimer

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.



Caplin Point
Laboratories Limited

Mr G Venkatram

investors@caplinpoint.net

**Churchgate
Investor Relations**

Simran Malhotra / Akshay Hirani

caplinpoint@churchgatepartners.com

BSE 524742

NSE CAPLIPOINT

CIN: L24231TN1990PLC019053

ISIN: INE475E01026 | DUNS:86-148-4556 | WWW.CAPLINPOINT.NET

©2018, Caplin Point Laboratories Limited – All Rights Reserved.

“Caplin Point” and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

